Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Animal Health

Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges

Merck Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed second-quarter earnings picture, with adjusted earnings surpassing analyst consensus but overall sales experiencing a slight year-over-year decline and missing revenue expectations.

Benzinga · Jul 29, 2025

Unveiling 4 Analyst Insights On Patterson Cos

During the last three months, 4 analysts shared their evaluations of Patterson Cos (NASDAQ:PDCO), revealing diverse outlooks from bullish to bearish.

Benzinga · Dec 6, 2024

What to Expect from Patterson Cos's Earnings

Patterson Cos (NASDAQ:PDCO) will release its quarterly earnings report on Thursday, 2024-12-05. Here's a brief overview for investors ahead of the announcement.

Benzinga · Dec 4, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Stocks That Can Thrive in Any Economy

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

StockNews.com · Oct 15, 2024

3 Low Volatility Stocks to Buy for a Smoother Ride

Low-volatility stocks are attractive now because they provide stability and reduce risk during market downturns, delivering steady returns amidst economic uncertainty and fluctuating interest rates. Hence, let's examine the fundamentals of low volatility stocks such as Merck & Co. (MRK), George Weston (WNGRF), and Unum (UNM), which are must-buys for…

StockNews.com · Sep 16, 2024

3 Undervalued Healthcare Stocks With Strong Upside Potential

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

StockNews.com · Sep 5, 2024

3 Bargain Healthcare Stocks to Buy for Long-Term Gains

The healthcare sector is poised for significant growth, driven by advancements in drug development, ongoing research and development (R&D) efforts, and its ability to remain resilient even during economic downturns. Thus, investors might consider buying bargain pharma stocks: Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) for…

StockNews.com · Aug 13, 2024

Read news from The Economist, FT, and more,
with one subscription

3 Healthcare Innovators With Game-Changing Treatments

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, rising R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks, Eli Lilly (LLY), Bristol-Myers (BMY), and Merck & Co. (MRK), which look poised for blockbuster…

StockNews.com · Jul 31, 2024

3 Healthcare Stocks Benefiting From an Aging Population

The healthcare industry is set for growth due to the growing demand for quality healthcare services and the aging population. Hence, quality healthcare stocks, such as Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co. (MRK), might be worth looking into. Read more….

StockNews.com · Jul 25, 2024

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

StockNews.com · Jul 18, 2024

3 A-Rated Pharma Stocks to Buy for Long-Term Growth

With surging medical needs, advances in precision medicine, and the adoption of generative AI, the pharmaceutical industry is thriving. Thus, it could be ideal to invest in quality pharma stocks Taro Pharmaceutical (TARO), AstraZeneca (AZN), and Merck (MRK) for long-term growth. These stocks are rated A (Strong Buy) in our…

StockNews.com · May 2, 2024

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

StockNews.com · Apr 24, 2024

3 Pharma Stocks Fueling Investor Enthusiasm

The pharmaceutical industry is expected to expand rapidly due to growing global healthcare needs and advancements in technology. Therefore, fundamentally strong pharma stocks Merck (MRK), AbbVie (ABBV), and GSK plc (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com · Mar 18, 2024

3 Pharma Stock Buys for Last-Minute Year-End Profits

Growing healthcare spending and the use of cutting-edge technologies in the research and development of new drugs have put the pharmaceutical industry in a strong position for growth. With such constructive trends in mind, it's wise to buy fundamentally strong pharma stocks, Merck (MRK), Collegium (COLL) and Johnson & Johnson…

StockNews.com · Dec 26, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · Dec 18, 2023

Are These 3 Pharma Stocks Smart Buys for Bullish Investors?

The pharmaceutical industry's outlook looks promising, given robust healthcare spending worldwide and the rapid adoption of advanced digital technologies. Amid this, let’s find out if pharma stocks AbbVie (ABBV), Collegium Pharmaceutical (COLL), and Merck (MRK) are ideal buys now. Read on to know more….

StockNews.com · Nov 15, 2023

Analyzing Pharma Stock Giants: JNJ, MRK, and ABBV

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

StockNews.com · Mar 23, 2023

3 Large-Cap Stocks You Can Buy for Under $200

The recent financial turmoil from several bank failures, the Fed’s persistent hawkish stance to battle stubborn inflation, and renewed recession worries have kept the stock market highly volatile lately. Amid this backdrop, investors could consider buying fundamentally sound, large-cap stocks Taiwan Semiconductor (TSM), Johnson & Johnson (JNJ), and Merck (MRK),…

StockNews.com · Jun 1, 2022

5 Resilient Stocks to Own During a Market Downturn

The stock market closed the last trading session of May in the red, underscoring inflation fears and rising oil prices. Furthermore, strategists expect the broad market to decline further, given the inflationary pressures and the Fed’s monetary tightening. Hence, we think stocks that have outpaced the broader market so far…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com · May 25, 2022

3 Low-Beta Stocks to Buy to Combat a Jittery Market

The Fed’s aggressive interest rate increases to tame multi-decade high inflation, and an anticipated economic slowdown, have exacerbated market volatility of late. To protect against the market uncertainties, we think investors should consider investing in low-beta stocks Merck (MRK), Gilead Sciences (GILD), and AmerisourceBergen (ABC). Let’s discuss why.

Benzinga · May 5, 2022

Phibro Animal Reports Mixed Q3 Earnings, Lifts FY22 Sales Outlook

Phibro Animal Health Corp (NASDAQ:PAHC) posted Q3 FY22 sales of $239.6 million, +13% Y/Y, beating the consensus of $226.26 million. Adjusted EPS decreased 3% to $0.33, missing the consensus of $0.35. The gross margin decreased 280 basis points to 29.9%. Adjusted EBITDA of $28.0 million, comparable to the prior year. "Our fiscal…

StockNews.com · May 3, 2022

5 Strong Stocks Bucking the Market Downtrend

The S&P 500 experienced its worst period since 1939 between January and April this year. The stock market has been under pressure due to investor fears about looming interest rate increases, geopolitical tensions, and rising inflation. Hence, we think it might be best now to bet on fundamentally sound stocks…

Coverage From

People

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.